Inflammation

Vevye, a preservative-free, twice-daily 0.1% cyclosporine ophthalmic solution indicated for treatment of signs and symptoms of dry eye disease, is now available in the U.S., according to a manufacturer press release.

Okyo Pharma announced positive safety and efficacy data from its phase 2 trial of OK-101 ophthalmic solution, a lipid-conjugated chemerin peptide agonist designed to reduce pain and inflammation in patients with dry eye disease.

Oculis has completed the first patient visit in its phase 3 OPTIMIZE-2 trial of OCS-01, the company’s preservative-free, once-daily topical formulation of dexamethasone for treating pain and inflammation after cataract surgery.

According to published results, use of diosmin after total knee arthroplasty was associated with reduced lower extremity swelling and reduced pain during motion with no increase in short-term complications.

Oculis has announced the first patient first visit in the second stage of its phase 3 DIAMOND-1 trial evaluating OCS-01, the company’s high-concentration formulation of dexamethasone for treatment of diabetic macular edema.

In this video, Esther M. Bowie, MD, discusses results of the GALE study, presented at the American Academy of Ophthalmology meeting.

RGRN-305 inhibits heat shock protein 90, and this action may modulate inflammation from hidradenitis suppurativa, according to a study.

Prolonged periods of gaming may contribute to the development of dry eye symptoms in young adults, according to a study presented at the 2023 EastWest Eye Care Conference.

SAN FRANCISCO — In this Healio Video Perspective from the AAO meeting, Benjamin Xu, MD, reports similar outcomes for patients using Dextenza compared with more conventional treatments after cataract surgery.

Inhalation of traffic-related air pollution in a car with unfiltered air was linked to a rapid increase in BP, which peaked within 1 hour, a recent study found.